Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT) (NCT00568464) | Clinical Trial Compass
TerminatedPhase 2
Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)
Stopped: The enrollment is slower than expected
China10 participantsStarted 2007-03
Plain-language summary
The purpose of this clinical trial was to evaluate the efficacy and tolerability of the sequential therapy of VCD/IE in the patients with ESFT.
Who can participate
Age range10 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age range 10-65 years old
* Histological confirmed ESFT
* No previous therapy
* ECOG performance status less than 2
* Life expectancy of more than 12 weeks
* Normal laboratory values: hemoglobin\>8.0g/dl, neutrophil\>2×109/L, platelet \> 80×109/L, Hb \> 80×1012/L, serum creatine \< 1×upper limitation of normal(ULN), serum bilirubin \< 1.5×ULN, ALT and AST \< 2.5×ULN
Exclusion Criteria:
* Pregnant or lactating women
* Received treatment for the disease previously
* Serious uncontrolled diseases and intercurrent infection
* The evidence of CNS metastasis and bone marrow involvement
* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
* History of allergy to the drugs in this trial
* Abnormal LVEF level